Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications

• Published in: Biomedicine & pharmacotherapy Vol. 103; pp. 662 - 679
• Main Authors: Kumari, Archana, Silakari, Om, Singh, Rajesh K.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.07.2018
• Subjects: Cancer; Clinical c-FMS inhibitors; CSF-1; CSF-1R inhibitors; CSF-1R/c-FMS; IL-34; Inflammatory disorders; CSF-1R inhibitors; Inflammatory disorders; Clinical c-FMS inhibitors; CSF-1; IL-34; CSF-1R/c-FMS; Cancer
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2018.04.046

•CSF-1R/c-FMS is a multifunctional protein tyrosine kinase transmembrane receptor.•CSF-1 and IL-34, two distinct cytokines, bind to the CSF-1R/cFMS.•Targeting CSF-1R or FMS using inhibitors have been a successful strategy in various therapeutic implications.•Recent developments in FMS inhibitors under clinical trials have been discussed. Colony stimulating factor-1 (CSF-1) is one of the most common proinflammatory cytokine responsible for various inflammatory disorders. It has a remarkable role in the development and progression of osteoarthritis, cancer and other autoimmune disease conditions. The CSF-1 acts by binding to the receptor, called colony stimulating factor-1 receptor (CSF-1R) also known as c-FMS resulting in the cascade of signalling pathway causing cell proliferation and differentiation. Interleukin-34 (IL-34), recently identified as another ligand for CSF-IR, is a cytokine protein. Both, CSF-1 and IL-34, although two distinct cytokines, follow the similar signalling pathway on binding to the same receptor, CSF-1R. Like CSF-1, IL-34 promotes the differentiation and survival of monocyte, macrophages and osteoclasts. This CSF-1R/c-FMS is over expressed in many cancers and on tumour associated macrophages, consequently, have been exploited as a drug target for promising treatment for cancer and inflammatory diseases. Some CSF-1R/c-FMS inhibitors such as ABT-869, Imatinib, AG013736, JNJ-40346527, PLX3397, DCC-3014 and Ki20227 have been successfully used in these disease conditions. Many c-FMS inhibitors have been the candidates of clinical trials, but suffer from some side effects like cardiotoxicity, vomiting, swollen eyes, diarrhoea, etc. If selectivity of cFMS inhibition is achieved successfully, side effects can be overruled and this approach may become a novel therapy for treatment of various therapeutic interventions. Thus, successful targeting of c-FMS may result in multifunctional therapy. With this background of information, the present review focuses on the recent developments in the area of CSF-1R/c-FMS inhibitors with emphasis on crystal structure, mechanism of action and various therapeutic implications in which c-FMS plays a pivotal role. The review on structure activity relationship of various compounds acting as the inhibitors of c-FMS which gives the selection criteria for the development of novel molecules is also being presented.